Evaluation of Glucose-6-Phosphate Dehydrogenase Serum Level in Multiple Sclerosis and Neuromyelitis Optica Patients

Abstract

Multiple sclerosis (MS) and Neuromyelitis Optica (NMO) are both demyelinating disorders and oxidative stress is suggested to have a role in their pathogenesis. Glucose 6 phosphate dehydrogenase (G6PD) produces nicotinamide adenine dinucleotide phosphate (NADPH) via the pentose phosphate pathway. NADPH is not only involved in the synthesis of fatty acids necessary for myelination but also it is involved in the defense against oxidative stress. Prescribing Supplementary Vitamin D as a part of the MS treatment plan can increase G6PD gene expression. The aim of this study is to determine the serum level of G6PD in MS and NMO patients and its relationship with vitamin D since it is yet to be explored thoroughly. In this case-control study subjects were divided into three experimental and control groups. The experimental groups comprised 50 Relapsing-remitting MS (RRMS) patients who had a history of Vitamin D consumption, 50 new MS patients, and 50 NMO patients. Control group included 65 healthy individuals. Serum level of G6PD was measured and compared among these groups. No significant difference was seen between the G6PD level in MS and NMO patients, but it should be noted that this level was significantly lower than the healthy group. G6PD Serum level was significantly higher in MS patients who had previously consumed supplementary vitamin D compared to those who had not. G6PD deficiency is observed in MS and NMO patients. Also, supplementary vitamin D may induce favorable results on the G6PD level.